Immunity vs Cancer: Predicting who will gain from costly therapy

In 10 seconds? We continue our chat about cancer immune checkpoint therapies–which help our immune system attack cancer. One area showing progress is the quest for discrete biological features (AKA biomarkers) that indicate positive treatment outcomes in patients.

What’s the story? In our last Immunity vs Cancer digest, we learned that 'immune checkpoint inhibitors–or ICI'  have been game-changers in treating some advanced-stage cancers–with response rates (AKA improvement in cancer burden) that range from 10% to 60%.